Metabolism in the Tumour-Bone Microenvironment
- PMID: 34319488
- PMCID: PMC8551098
- DOI: 10.1007/s11914-021-00695-7
Metabolism in the Tumour-Bone Microenvironment
Abstract
Purpose of review: For solid tumours such as breast and prostate cancer, and haematological malignancies such as myeloma, bone represents a supportive home, where the cellular crosstalk is known to underlie both tumour growth and survival, and the development of the associated bone disease. The importance of metabolic reprogramming is becoming increasingly recognised, particularly within cancer biology, enabling tumours to adapt to changing environments and pressures. This review will discuss our current understanding of metabolic requirements and adaptations within the tumour-bone microenvironment.
Recent findings: The bone provides a unique metabolic microenvironment, home to highly energy-intensive processes such as bone resorption and bone formation, both of which are dysregulated in the presence of cancer. Approaches such as metabolomics demonstrate metabolic plasticity in patients with advanced disease. Metabolic crosstalk between tumour cells and surrounding stroma supports disease pathogenesis. There is increasing evidence for a key role for metabolic reprogramming within the tumour-bone microenvironment to drive disease progression. As such, understanding these metabolic adaptations should reveal new therapeutic targets and approaches.
Keywords: Bone; Cancer; Glycolysis; Metabolism; Metastasis; Microenvironment.
© 2021. The Author(s).
Conflict of interest statement
Claire Edwards and Jessica Whitburn declare no conflict of interest.
Similar articles
-
Metabolic crosstalk in the breast cancer microenvironment.Eur J Cancer. 2019 Nov;121:154-171. doi: 10.1016/j.ejca.2019.09.002. Epub 2019 Sep 30. Eur J Cancer. 2019. PMID: 31581056 Review.
-
Metabolic reprogramming, malignant transformation and metastasis: Lessons from chronic lymphocytic leukaemia and prostate cancer.Cancer Lett. 2025 Jan 2;611:217441. doi: 10.1016/j.canlet.2025.217441. Online ahead of print. Cancer Lett. 2025. PMID: 39755364 Review.
-
Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis.Cell Mol Life Sci. 2020 Dec;77(24):5149-5169. doi: 10.1007/s00018-020-03572-1. Epub 2020 Jun 16. Cell Mol Life Sci. 2020. PMID: 32556373 Free PMC article. Review.
-
Metabolic reprogramming: the emerging concept and associated therapeutic strategies.J Exp Clin Cancer Res. 2015 Oct 6;34:111. doi: 10.1186/s13046-015-0221-y. J Exp Clin Cancer Res. 2015. PMID: 26445347 Free PMC article. Review.
-
Novel approaches to target the microenvironment of bone metastasis.Nat Rev Clin Oncol. 2021 Aug;18(8):488-505. doi: 10.1038/s41571-021-00499-9. Epub 2021 Apr 19. Nat Rev Clin Oncol. 2021. PMID: 33875860 Review.
Cited by
-
Functionalized zeolite regulates bone metabolic microenvironment.Mater Today Bio. 2025 Feb 5;31:101558. doi: 10.1016/j.mtbio.2025.101558. eCollection 2025 Apr. Mater Today Bio. 2025. PMID: 40034985 Free PMC article. Review.
-
Comprehensive Integrated Analysis Reveals the Spatiotemporal Microevolution of Cancer Cells in Patients with Bone-Metastatic Prostate Cancer.Biomedicines. 2025 Apr 9;13(4):909. doi: 10.3390/biomedicines13040909. Biomedicines. 2025. PMID: 40299503 Free PMC article.
-
Emerging roles for stromal cells in bone metastasis.J Bone Oncol. 2024 May 17;47:100610. doi: 10.1016/j.jbo.2024.100610. eCollection 2024 Aug. J Bone Oncol. 2024. PMID: 38984147 Free PMC article.
-
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma.Front Oncol. 2021 Oct 12;11:760732. doi: 10.3389/fonc.2021.760732. eCollection 2021. Front Oncol. 2021. PMID: 34712616 Free PMC article.
-
Krüppel-like factors family in health and disease.MedComm (2020). 2024 Sep 10;5(9):e723. doi: 10.1002/mco2.723. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39263604 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials